Worldwide Drug Modeling Software Industry to 2027 - Increasing Adoption of Modelling Tools in Drug Discovery is Driving Growth

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- The "Drug Modeling Software Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global drug modeling software biopharmaceutical market is expected to reach US$ 11,299.85 million by 2027 from US$ 6,205.22 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The report highlights the trends prevalent in the global drug modeling software market, and the drivers and deterrents pertaining to its growth.

Based on product type, the drug modeling software market is segmented into database, software, and others. In terms of product type, the software segment held the highest share of the drug modeling software market in 2019 and is estimated to register the highest CAGR of 8.4% in the market during the forecast period. The growth of the market is attributed to the growing demand for effective therapeutics and increasing number of drug discovery efforts of various biologics across a wide range of therapeutics. Additionally, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expedite drug discovery timeline are further accelerating the growth of the market.

The market growth is also attributed to a few key factors such as increasing adoption of in-silico modeling tools in drug discovery, and rising economic burden of drug discovery. However, less adoption in emerging countries is expected to hamper the growth of the market up to certain extent during the forecast period.

Crown Bioscience Inc.; Chemical Computing Group Ulc; Nimbus Therapeutics; Schrdinger, Inc.; Dassault Systmes; Genedata Ag; Biognos Ab; Compugen Ltd; Acellera ltd.; and Leadscope, Inc plc are among the prominent players operating in the drug modeling software market. The market players are focused on organic strategies to sustain their position in the market. For instance, in March 2020, Crown Bioscience has launched two new liver fibrosis rodent models, which allows rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the drug modeling software market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global drug modeling software market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Drug Modelling Software Market - By Product Type
1.3.2 Global Drug Modelling Software Market - By Application
1.3.3 Global Drug Modelling Software market - By Geography

2. Drug Modelling Software Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Drug Modelling Software Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South and Central America (SCAM) - PEST Analysis
4.3 Expert Opinions

5. Drug Modelling Software Market- Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing Adoption of Modelling Tools in Drug Discovery
5.1.2 Increasing Economic Burden of Drug Discovery
5.2 Key Market Restraints
5.2.1 Less Adoption in Emerging Countries
5.3 Key Market Opportunities
5.3.1 Strategic Activities by Market Players
5.4 Future Trends
5.4.1 Growing Adoption of Artificial Intelligence in Drug Discovery
5.5 Impact analysis

6. Drug Modelling Software Market - Global Analysis
6.1 Global Drug Modelling Software Market Revenue Forecast And Analysis
6.2 Global Drug Modelling Software Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Drug Modelling Software Market - By Product Type
7.1 Overview
7.2 Drug Modelling Software Market, by Product Type, 2019 and 2027 (%)
7.3 Database
7.3.1 Overview
7.3.2 Database: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Software
7.5.1 Overview
7.5.2 Software: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
7.6 Other Product Types
7.6.1 Overview
7.6.2 Other Product Types: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)

8. Drug Modelling Software Market Analysis - By Application
8.1 Overview
8.2 Drug Modelling Software Market Revenue Share, by Application (2019 and 2027)
8.3 Drug Discovery and Development
8.3.1 Overview
8.3.2 Drug Discovery and Development: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Computational Physiological Medicine
8.4.1 Overview
8.4.2 Computational Physiological Medicine: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Disease Modelling
8.5.1 Overview
8.5.2 Disease Modelling: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.6 Medical Imaging
8.6.1 Overview
8.6.2 Medical Imaging: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.7 Predictive Analysis of Drug Targets
8.7.1 Overview
8.7.2 Predictive Analysis of Drug Targets: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.8 Simulation Software
8.8.1 Overview
8.8.2 Simulation Software: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.9 Cellular Simulation
8.9.1 Overview
8.9.2 Cellular Simulation: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)
8.10 Others
8.10.1 Overview
8.10.2 Others: Drug Modelling Software Market - Revenue and Forecast to 2027 (US$ Million)

9. Drug Modelling Software Market Analysis And Forecasts To 2027 - Geographical Analysis
9.1 North America: Drug Modelling Software Market
9.2 Europe: Drug Modelling Software Market
9.3 Asia-Pacific: Drug Modelling Software Market
9.4 Middle East & Africa: Drug Modelling Software Market
9.5 South and Central America: Drug Modelling Software Market

10. Impact Of COVID-19 Pandemic On Global Drug Modelling Software Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment Of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

11. Drug Modelling Software Market - Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview

12. Company Profiles
12.1 Crown Bioscience Inc (JSR life science)
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Chemical Computing Group ULC.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Nimbus Therapeutics
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Schrdinger, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Genedata AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Biognos AB
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Compugen Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Dassault Systmes
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Acellera
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.10 Leadscope, Inc (Instem)
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments

13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/176pew

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com